Viewing Study NCT06215118

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 5:02 AM
Ignite Modification Date: 2026-01-28 @ 12:38 PM
Study NCT ID: NCT06215118
Status: RECRUITING
Last Update Posted: 2025-12-18
First Post: 2024-01-10
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Sponsor: Pfizer
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Myeloma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None elranatamab View
None PF-06863135 View
None iberdomide View
None relapsed View
None refractory View
None RRMM View
None BCMA View
None MagnetisMM View
None Bispecific antibody View
None CC-220 View